Global Oligonucleotide Therapy-based Drug Market Growth (Status and Outlook) 2026-2032
The global Oligonucleotide Therapy-based Drug market size is predicted to grow from US$ 13040 million in 2025 to US$ 16910 million in 2032; it is expected to grow at a CAGR of 3.8% from 2026 to 2032.
Oligonucleotides can be used to modulate gene expression via a range of processes including RNAi, target degradation by RNase H-mediated cleavage, splicing modulation, non-coding RNA inhibition, gene activation and programmed gene editing.
The Oligonucleotide Drug Delivery Market is driven by the rapid advancement in oligonucleotide-based therapies, including antisense, siRNA, and aptamer-based drugs, which hold immense potential for treating various genetic and rare diseases. These therapies rely on oligonucleotides to modulate gene expression, inhibit specific targets, or diagnose genetic disorders. As the understanding of genetic mechanisms and precision medicine continues to evolve, the demand for efficient and targeted delivery systems for oligonucleotide drugs grows. Innovations in drug delivery technologies, such as lipid nanoparticles and conjugates, as well as the expansion of oligonucleotide drug pipelines, further contribute to market expansion. However, a significant challenge for this market is the need to address the complexity of drug delivery, including overcoming biological barriers, minimizing off-target effects, and ensuring long-term safety and efficacy. Overcoming delivery hurdles, optimizing pharmacokinetics, and navigating regulatory pathways are ongoing challenges. Additionally, the market faces competition from traditional drug therapies, and the need for continuous research and development to enhance the delivery efficiency and patient acceptance of oligonucleotide drugs. Striking a balance between providing efficient and precise oligonucleotide drug delivery solutions while addressing safety and regulatory considerations is crucial for the continued growth of the Oligonucleotide Drug Delivery Market.
LPI (LP Information)' newest research report, the “Oligonucleotide Therapy-based Drug Industry Forecast” looks at past sales and reviews total world Oligonucleotide Therapy-based Drug sales in 2025, providing a comprehensive analysis by region and market sector of projected Oligonucleotide Therapy-based Drug sales for 2026 through 2032. With Oligonucleotide Therapy-based Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Oligonucleotide Therapy-based Drug industry.
This Insight Report provides a comprehensive analysis of the global Oligonucleotide Therapy-based Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Oligonucleotide Therapy-based Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Oligonucleotide Therapy-based Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Oligonucleotide Therapy-based Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Oligonucleotide Therapy-based Drug.
This report presents a comprehensive overview, market shares, and growth opportunities of Oligonucleotide Therapy-based Drug market by product type, application, key players and key regions and countries.
Segmentation by Type:
Oligonucleotides can be used to modulate gene expression via a range of processes including RNAi, target degradation by RNase H-mediated cleavage, splicing modulation, non-coding RNA inhibition, gene activation and programmed gene editing.
The Oligonucleotide Drug Delivery Market is driven by the rapid advancement in oligonucleotide-based therapies, including antisense, siRNA, and aptamer-based drugs, which hold immense potential for treating various genetic and rare diseases. These therapies rely on oligonucleotides to modulate gene expression, inhibit specific targets, or diagnose genetic disorders. As the understanding of genetic mechanisms and precision medicine continues to evolve, the demand for efficient and targeted delivery systems for oligonucleotide drugs grows. Innovations in drug delivery technologies, such as lipid nanoparticles and conjugates, as well as the expansion of oligonucleotide drug pipelines, further contribute to market expansion. However, a significant challenge for this market is the need to address the complexity of drug delivery, including overcoming biological barriers, minimizing off-target effects, and ensuring long-term safety and efficacy. Overcoming delivery hurdles, optimizing pharmacokinetics, and navigating regulatory pathways are ongoing challenges. Additionally, the market faces competition from traditional drug therapies, and the need for continuous research and development to enhance the delivery efficiency and patient acceptance of oligonucleotide drugs. Striking a balance between providing efficient and precise oligonucleotide drug delivery solutions while addressing safety and regulatory considerations is crucial for the continued growth of the Oligonucleotide Drug Delivery Market.
LPI (LP Information)' newest research report, the “Oligonucleotide Therapy-based Drug Industry Forecast” looks at past sales and reviews total world Oligonucleotide Therapy-based Drug sales in 2025, providing a comprehensive analysis by region and market sector of projected Oligonucleotide Therapy-based Drug sales for 2026 through 2032. With Oligonucleotide Therapy-based Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Oligonucleotide Therapy-based Drug industry.
This Insight Report provides a comprehensive analysis of the global Oligonucleotide Therapy-based Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Oligonucleotide Therapy-based Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Oligonucleotide Therapy-based Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Oligonucleotide Therapy-based Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Oligonucleotide Therapy-based Drug.
This report presents a comprehensive overview, market shares, and growth opportunities of Oligonucleotide Therapy-based Drug market by product type, application, key players and key regions and countries.
Segmentation by Type:
- Antisense Oligonucleotides (ASO)
- siRNA
- mRNA
- Neuromuscular Diseases
- hATTR
- COVID-19
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Sarepta Therapeutics
- Ionis Pharmaceuticals
- Alnylam
- Biogen
- Nippon Shinyaku
- Sobi
- Novartis
- BioNTech
- Pfizer
- Moderna Therapeutics
- Jazz Pharmaceuticals
- CureVac
- Regulus Therapeutics
- ProQR
- Secarna
- MiNA Therapeutics
- Sylentis
- Arrowhead
- Silence Therapeutics
- Dicerna
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Oligonucleotide Therapy-based Drug Market Size (2021-2032)
2.1.2 Oligonucleotide Therapy-based Drug Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Oligonucleotide Therapy-based Drug by Country/Region (2021, 2025 & 2032)
2.2 Oligonucleotide Therapy-based Drug Segment by Type
2.2.1 Antisense Oligonucleotides (ASO)
2.2.2 siRNA
2.2.3 mRNA
2.2.4 Oligonucleotide Therapy-based Drug Market Size by Type
2.2.4.1 Oligonucleotide Therapy-based Drug Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.4.2 Global Oligonucleotide Therapy-based Drug Market Size Market Share by Type (2021-2026)
2.3 Oligonucleotide Therapy-based Drug Segment by Application
2.3.1 Neuromuscular Diseases
2.3.2 hATTR
2.3.3 COVID-19
2.3.4 Other
2.3.5 Oligonucleotide Therapy-based Drug Market Size by Application
2.3.5.1 Oligonucleotide Therapy-based Drug Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.3.5.2 Global Oligonucleotide Therapy-based Drug Market Size Market Share by Application (2021-2026)
3 OLIGONUCLEOTIDE THERAPY-BASED DRUG MARKET SIZE BY PLAYER
3.1 Oligonucleotide Therapy-based Drug Market Size Market Share by Player
3.1.1 Global Oligonucleotide Therapy-based Drug Revenue by Player (2021-2026)
3.1.2 Global Oligonucleotide Therapy-based Drug Revenue Market Share by Player (2021-2026)
3.2 Global Oligonucleotide Therapy-based Drug Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 OLIGONUCLEOTIDE THERAPY-BASED DRUG BY REGION
4.1 Oligonucleotide Therapy-based Drug Market Size by Region (2021-2026)
4.2 Global Oligonucleotide Therapy-based Drug Annual Revenue by Country/Region (2021-2026)
4.3 Americas Oligonucleotide Therapy-based Drug Market Size Growth (2021-2026)
4.4 APAC Oligonucleotide Therapy-based Drug Market Size Growth (2021-2026)
4.5 Europe Oligonucleotide Therapy-based Drug Market Size Growth (2021-2026)
4.6 Middle East & Africa Oligonucleotide Therapy-based Drug Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Oligonucleotide Therapy-based Drug Market Size by Country (2021-2026)
5.2 Americas Oligonucleotide Therapy-based Drug Market Size by Type (2021-2026)
5.3 Americas Oligonucleotide Therapy-based Drug Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Oligonucleotide Therapy-based Drug Market Size by Region (2021-2026)
6.2 APAC Oligonucleotide Therapy-based Drug Market Size by Type (2021-2026)
6.3 APAC Oligonucleotide Therapy-based Drug Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Oligonucleotide Therapy-based Drug Market Size by Country (2021-2026)
7.2 Europe Oligonucleotide Therapy-based Drug Market Size by Type (2021-2026)
7.3 Europe Oligonucleotide Therapy-based Drug Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Oligonucleotide Therapy-based Drug by Region (2021-2026)
8.2 Middle East & Africa Oligonucleotide Therapy-based Drug Market Size by Type (2021-2026)
8.3 Middle East & Africa Oligonucleotide Therapy-based Drug Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL OLIGONUCLEOTIDE THERAPY-BASED DRUG MARKET FORECAST
10.1 Global Oligonucleotide Therapy-based Drug Forecast by Region (2027-2032)
10.1.1 Global Oligonucleotide Therapy-based Drug Forecast by Region (2027-2032)
10.1.2 Americas Oligonucleotide Therapy-based Drug Forecast
10.1.3 APAC Oligonucleotide Therapy-based Drug Forecast
10.1.4 Europe Oligonucleotide Therapy-based Drug Forecast
10.1.5 Middle East & Africa Oligonucleotide Therapy-based Drug Forecast
10.2 Americas Oligonucleotide Therapy-based Drug Forecast by Country (2027-2032)
10.2.1 United States Market Oligonucleotide Therapy-based Drug Forecast
10.2.2 Canada Market Oligonucleotide Therapy-based Drug Forecast
10.2.3 Mexico Market Oligonucleotide Therapy-based Drug Forecast
10.2.4 Brazil Market Oligonucleotide Therapy-based Drug Forecast
10.3 APAC Oligonucleotide Therapy-based Drug Forecast by Region (2027-2032)
10.3.1 China Oligonucleotide Therapy-based Drug Market Forecast
10.3.2 Japan Market Oligonucleotide Therapy-based Drug Forecast
10.3.3 Korea Market Oligonucleotide Therapy-based Drug Forecast
10.3.4 Southeast Asia Market Oligonucleotide Therapy-based Drug Forecast
10.3.5 India Market Oligonucleotide Therapy-based Drug Forecast
10.3.6 Australia Market Oligonucleotide Therapy-based Drug Forecast
10.4 Europe Oligonucleotide Therapy-based Drug Forecast by Country (2027-2032)
10.4.1 Germany Market Oligonucleotide Therapy-based Drug Forecast
10.4.2 France Market Oligonucleotide Therapy-based Drug Forecast
10.4.3 UK Market Oligonucleotide Therapy-based Drug Forecast
10.4.4 Italy Market Oligonucleotide Therapy-based Drug Forecast
10.4.5 Russia Market Oligonucleotide Therapy-based Drug Forecast
10.5 Middle East & Africa Oligonucleotide Therapy-based Drug Forecast by Region (2027-2032)
10.5.1 Egypt Market Oligonucleotide Therapy-based Drug Forecast
10.5.2 South Africa Market Oligonucleotide Therapy-based Drug Forecast
10.5.3 Israel Market Oligonucleotide Therapy-based Drug Forecast
10.5.4 Turkey Market Oligonucleotide Therapy-based Drug Forecast
10.6 Global Oligonucleotide Therapy-based Drug Forecast by Type (2027-2032)
10.7 Global Oligonucleotide Therapy-based Drug Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Oligonucleotide Therapy-based Drug Forecast
11 KEY PLAYERS ANALYSIS
11.1 Sarepta Therapeutics
11.1.1 Sarepta Therapeutics Company Information
11.1.2 Sarepta Therapeutics Oligonucleotide Therapy-based Drug Product Offered
11.1.3 Sarepta Therapeutics Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Sarepta Therapeutics Main Business Overview
11.1.5 Sarepta Therapeutics Latest Developments
11.2 Ionis Pharmaceuticals
11.2.1 Ionis Pharmaceuticals Company Information
11.2.2 Ionis Pharmaceuticals Oligonucleotide Therapy-based Drug Product Offered
11.2.3 Ionis Pharmaceuticals Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Ionis Pharmaceuticals Main Business Overview
11.2.5 Ionis Pharmaceuticals Latest Developments
11.3 Alnylam
11.3.1 Alnylam Company Information
11.3.2 Alnylam Oligonucleotide Therapy-based Drug Product Offered
11.3.3 Alnylam Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Alnylam Main Business Overview
11.3.5 Alnylam Latest Developments
11.4 Biogen
11.4.1 Biogen Company Information
11.4.2 Biogen Oligonucleotide Therapy-based Drug Product Offered
11.4.3 Biogen Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 Biogen Main Business Overview
11.4.5 Biogen Latest Developments
11.5 Nippon Shinyaku
11.5.1 Nippon Shinyaku Company Information
11.5.2 Nippon Shinyaku Oligonucleotide Therapy-based Drug Product Offered
11.5.3 Nippon Shinyaku Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Nippon Shinyaku Main Business Overview
11.5.5 Nippon Shinyaku Latest Developments
11.6 Sobi
11.6.1 Sobi Company Information
11.6.2 Sobi Oligonucleotide Therapy-based Drug Product Offered
11.6.3 Sobi Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Sobi Main Business Overview
11.6.5 Sobi Latest Developments
11.7 Novartis
11.7.1 Novartis Company Information
11.7.2 Novartis Oligonucleotide Therapy-based Drug Product Offered
11.7.3 Novartis Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Novartis Main Business Overview
11.7.5 Novartis Latest Developments
11.8 BioNTech
11.8.1 BioNTech Company Information
11.8.2 BioNTech Oligonucleotide Therapy-based Drug Product Offered
11.8.3 BioNTech Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 BioNTech Main Business Overview
11.8.5 BioNTech Latest Developments
11.9 Pfizer
11.9.1 Pfizer Company Information
11.9.2 Pfizer Oligonucleotide Therapy-based Drug Product Offered
11.9.3 Pfizer Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 Pfizer Main Business Overview
11.9.5 Pfizer Latest Developments
11.10 Moderna Therapeutics
11.10.1 Moderna Therapeutics Company Information
11.10.2 Moderna Therapeutics Oligonucleotide Therapy-based Drug Product Offered
11.10.3 Moderna Therapeutics Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 Moderna Therapeutics Main Business Overview
11.10.5 Moderna Therapeutics Latest Developments
11.11 Jazz Pharmaceuticals
11.11.1 Jazz Pharmaceuticals Company Information
11.11.2 Jazz Pharmaceuticals Oligonucleotide Therapy-based Drug Product Offered
11.11.3 Jazz Pharmaceuticals Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2021-2026)
11.11.4 Jazz Pharmaceuticals Main Business Overview
11.11.5 Jazz Pharmaceuticals Latest Developments
11.12 CureVac
11.12.1 CureVac Company Information
11.12.2 CureVac Oligonucleotide Therapy-based Drug Product Offered
11.12.3 CureVac Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2021-2026)
11.12.4 CureVac Main Business Overview
11.12.5 CureVac Latest Developments
11.13 Regulus Therapeutics
11.13.1 Regulus Therapeutics Company Information
11.13.2 Regulus Therapeutics Oligonucleotide Therapy-based Drug Product Offered
11.13.3 Regulus Therapeutics Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2021-2026)
11.13.4 Regulus Therapeutics Main Business Overview
11.13.5 Regulus Therapeutics Latest Developments
11.14 ProQR
11.14.1 ProQR Company Information
11.14.2 ProQR Oligonucleotide Therapy-based Drug Product Offered
11.14.3 ProQR Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2021-2026)
11.14.4 ProQR Main Business Overview
11.14.5 ProQR Latest Developments
11.15 Secarna
11.15.1 Secarna Company Information
11.15.2 Secarna Oligonucleotide Therapy-based Drug Product Offered
11.15.3 Secarna Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2021-2026)
11.15.4 Secarna Main Business Overview
11.15.5 Secarna Latest Developments
11.16 MiNA Therapeutics
11.16.1 MiNA Therapeutics Company Information
11.16.2 MiNA Therapeutics Oligonucleotide Therapy-based Drug Product Offered
11.16.3 MiNA Therapeutics Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2021-2026)
11.16.4 MiNA Therapeutics Main Business Overview
11.16.5 MiNA Therapeutics Latest Developments
11.17 Sylentis
11.17.1 Sylentis Company Information
11.17.2 Sylentis Oligonucleotide Therapy-based Drug Product Offered
11.17.3 Sylentis Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2021-2026)
11.17.4 Sylentis Main Business Overview
11.17.5 Sylentis Latest Developments
11.18 Arrowhead
11.18.1 Arrowhead Company Information
11.18.2 Arrowhead Oligonucleotide Therapy-based Drug Product Offered
11.18.3 Arrowhead Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2021-2026)
11.18.4 Arrowhead Main Business Overview
11.18.5 Arrowhead Latest Developments
11.19 Silence Therapeutics
11.19.1 Silence Therapeutics Company Information
11.19.2 Silence Therapeutics Oligonucleotide Therapy-based Drug Product Offered
11.19.3 Silence Therapeutics Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2021-2026)
11.19.4 Silence Therapeutics Main Business Overview
11.19.5 Silence Therapeutics Latest Developments
11.20 Dicerna
11.20.1 Dicerna Company Information
11.20.2 Dicerna Oligonucleotide Therapy-based Drug Product Offered
11.20.3 Dicerna Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2021-2026)
11.20.4 Dicerna Main Business Overview
11.20.5 Dicerna Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Oligonucleotide Therapy-based Drug Market Size (2021-2032)
2.1.2 Oligonucleotide Therapy-based Drug Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Oligonucleotide Therapy-based Drug by Country/Region (2021, 2025 & 2032)
2.2 Oligonucleotide Therapy-based Drug Segment by Type
2.2.1 Antisense Oligonucleotides (ASO)
2.2.2 siRNA
2.2.3 mRNA
2.2.4 Oligonucleotide Therapy-based Drug Market Size by Type
2.2.4.1 Oligonucleotide Therapy-based Drug Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.4.2 Global Oligonucleotide Therapy-based Drug Market Size Market Share by Type (2021-2026)
2.3 Oligonucleotide Therapy-based Drug Segment by Application
2.3.1 Neuromuscular Diseases
2.3.2 hATTR
2.3.3 COVID-19
2.3.4 Other
2.3.5 Oligonucleotide Therapy-based Drug Market Size by Application
2.3.5.1 Oligonucleotide Therapy-based Drug Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.3.5.2 Global Oligonucleotide Therapy-based Drug Market Size Market Share by Application (2021-2026)
3 OLIGONUCLEOTIDE THERAPY-BASED DRUG MARKET SIZE BY PLAYER
3.1 Oligonucleotide Therapy-based Drug Market Size Market Share by Player
3.1.1 Global Oligonucleotide Therapy-based Drug Revenue by Player (2021-2026)
3.1.2 Global Oligonucleotide Therapy-based Drug Revenue Market Share by Player (2021-2026)
3.2 Global Oligonucleotide Therapy-based Drug Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 OLIGONUCLEOTIDE THERAPY-BASED DRUG BY REGION
4.1 Oligonucleotide Therapy-based Drug Market Size by Region (2021-2026)
4.2 Global Oligonucleotide Therapy-based Drug Annual Revenue by Country/Region (2021-2026)
4.3 Americas Oligonucleotide Therapy-based Drug Market Size Growth (2021-2026)
4.4 APAC Oligonucleotide Therapy-based Drug Market Size Growth (2021-2026)
4.5 Europe Oligonucleotide Therapy-based Drug Market Size Growth (2021-2026)
4.6 Middle East & Africa Oligonucleotide Therapy-based Drug Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Oligonucleotide Therapy-based Drug Market Size by Country (2021-2026)
5.2 Americas Oligonucleotide Therapy-based Drug Market Size by Type (2021-2026)
5.3 Americas Oligonucleotide Therapy-based Drug Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Oligonucleotide Therapy-based Drug Market Size by Region (2021-2026)
6.2 APAC Oligonucleotide Therapy-based Drug Market Size by Type (2021-2026)
6.3 APAC Oligonucleotide Therapy-based Drug Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Oligonucleotide Therapy-based Drug Market Size by Country (2021-2026)
7.2 Europe Oligonucleotide Therapy-based Drug Market Size by Type (2021-2026)
7.3 Europe Oligonucleotide Therapy-based Drug Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Oligonucleotide Therapy-based Drug by Region (2021-2026)
8.2 Middle East & Africa Oligonucleotide Therapy-based Drug Market Size by Type (2021-2026)
8.3 Middle East & Africa Oligonucleotide Therapy-based Drug Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL OLIGONUCLEOTIDE THERAPY-BASED DRUG MARKET FORECAST
10.1 Global Oligonucleotide Therapy-based Drug Forecast by Region (2027-2032)
10.1.1 Global Oligonucleotide Therapy-based Drug Forecast by Region (2027-2032)
10.1.2 Americas Oligonucleotide Therapy-based Drug Forecast
10.1.3 APAC Oligonucleotide Therapy-based Drug Forecast
10.1.4 Europe Oligonucleotide Therapy-based Drug Forecast
10.1.5 Middle East & Africa Oligonucleotide Therapy-based Drug Forecast
10.2 Americas Oligonucleotide Therapy-based Drug Forecast by Country (2027-2032)
10.2.1 United States Market Oligonucleotide Therapy-based Drug Forecast
10.2.2 Canada Market Oligonucleotide Therapy-based Drug Forecast
10.2.3 Mexico Market Oligonucleotide Therapy-based Drug Forecast
10.2.4 Brazil Market Oligonucleotide Therapy-based Drug Forecast
10.3 APAC Oligonucleotide Therapy-based Drug Forecast by Region (2027-2032)
10.3.1 China Oligonucleotide Therapy-based Drug Market Forecast
10.3.2 Japan Market Oligonucleotide Therapy-based Drug Forecast
10.3.3 Korea Market Oligonucleotide Therapy-based Drug Forecast
10.3.4 Southeast Asia Market Oligonucleotide Therapy-based Drug Forecast
10.3.5 India Market Oligonucleotide Therapy-based Drug Forecast
10.3.6 Australia Market Oligonucleotide Therapy-based Drug Forecast
10.4 Europe Oligonucleotide Therapy-based Drug Forecast by Country (2027-2032)
10.4.1 Germany Market Oligonucleotide Therapy-based Drug Forecast
10.4.2 France Market Oligonucleotide Therapy-based Drug Forecast
10.4.3 UK Market Oligonucleotide Therapy-based Drug Forecast
10.4.4 Italy Market Oligonucleotide Therapy-based Drug Forecast
10.4.5 Russia Market Oligonucleotide Therapy-based Drug Forecast
10.5 Middle East & Africa Oligonucleotide Therapy-based Drug Forecast by Region (2027-2032)
10.5.1 Egypt Market Oligonucleotide Therapy-based Drug Forecast
10.5.2 South Africa Market Oligonucleotide Therapy-based Drug Forecast
10.5.3 Israel Market Oligonucleotide Therapy-based Drug Forecast
10.5.4 Turkey Market Oligonucleotide Therapy-based Drug Forecast
10.6 Global Oligonucleotide Therapy-based Drug Forecast by Type (2027-2032)
10.7 Global Oligonucleotide Therapy-based Drug Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Oligonucleotide Therapy-based Drug Forecast
11 KEY PLAYERS ANALYSIS
11.1 Sarepta Therapeutics
11.1.1 Sarepta Therapeutics Company Information
11.1.2 Sarepta Therapeutics Oligonucleotide Therapy-based Drug Product Offered
11.1.3 Sarepta Therapeutics Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Sarepta Therapeutics Main Business Overview
11.1.5 Sarepta Therapeutics Latest Developments
11.2 Ionis Pharmaceuticals
11.2.1 Ionis Pharmaceuticals Company Information
11.2.2 Ionis Pharmaceuticals Oligonucleotide Therapy-based Drug Product Offered
11.2.3 Ionis Pharmaceuticals Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Ionis Pharmaceuticals Main Business Overview
11.2.5 Ionis Pharmaceuticals Latest Developments
11.3 Alnylam
11.3.1 Alnylam Company Information
11.3.2 Alnylam Oligonucleotide Therapy-based Drug Product Offered
11.3.3 Alnylam Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Alnylam Main Business Overview
11.3.5 Alnylam Latest Developments
11.4 Biogen
11.4.1 Biogen Company Information
11.4.2 Biogen Oligonucleotide Therapy-based Drug Product Offered
11.4.3 Biogen Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 Biogen Main Business Overview
11.4.5 Biogen Latest Developments
11.5 Nippon Shinyaku
11.5.1 Nippon Shinyaku Company Information
11.5.2 Nippon Shinyaku Oligonucleotide Therapy-based Drug Product Offered
11.5.3 Nippon Shinyaku Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Nippon Shinyaku Main Business Overview
11.5.5 Nippon Shinyaku Latest Developments
11.6 Sobi
11.6.1 Sobi Company Information
11.6.2 Sobi Oligonucleotide Therapy-based Drug Product Offered
11.6.3 Sobi Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Sobi Main Business Overview
11.6.5 Sobi Latest Developments
11.7 Novartis
11.7.1 Novartis Company Information
11.7.2 Novartis Oligonucleotide Therapy-based Drug Product Offered
11.7.3 Novartis Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Novartis Main Business Overview
11.7.5 Novartis Latest Developments
11.8 BioNTech
11.8.1 BioNTech Company Information
11.8.2 BioNTech Oligonucleotide Therapy-based Drug Product Offered
11.8.3 BioNTech Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 BioNTech Main Business Overview
11.8.5 BioNTech Latest Developments
11.9 Pfizer
11.9.1 Pfizer Company Information
11.9.2 Pfizer Oligonucleotide Therapy-based Drug Product Offered
11.9.3 Pfizer Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 Pfizer Main Business Overview
11.9.5 Pfizer Latest Developments
11.10 Moderna Therapeutics
11.10.1 Moderna Therapeutics Company Information
11.10.2 Moderna Therapeutics Oligonucleotide Therapy-based Drug Product Offered
11.10.3 Moderna Therapeutics Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 Moderna Therapeutics Main Business Overview
11.10.5 Moderna Therapeutics Latest Developments
11.11 Jazz Pharmaceuticals
11.11.1 Jazz Pharmaceuticals Company Information
11.11.2 Jazz Pharmaceuticals Oligonucleotide Therapy-based Drug Product Offered
11.11.3 Jazz Pharmaceuticals Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2021-2026)
11.11.4 Jazz Pharmaceuticals Main Business Overview
11.11.5 Jazz Pharmaceuticals Latest Developments
11.12 CureVac
11.12.1 CureVac Company Information
11.12.2 CureVac Oligonucleotide Therapy-based Drug Product Offered
11.12.3 CureVac Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2021-2026)
11.12.4 CureVac Main Business Overview
11.12.5 CureVac Latest Developments
11.13 Regulus Therapeutics
11.13.1 Regulus Therapeutics Company Information
11.13.2 Regulus Therapeutics Oligonucleotide Therapy-based Drug Product Offered
11.13.3 Regulus Therapeutics Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2021-2026)
11.13.4 Regulus Therapeutics Main Business Overview
11.13.5 Regulus Therapeutics Latest Developments
11.14 ProQR
11.14.1 ProQR Company Information
11.14.2 ProQR Oligonucleotide Therapy-based Drug Product Offered
11.14.3 ProQR Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2021-2026)
11.14.4 ProQR Main Business Overview
11.14.5 ProQR Latest Developments
11.15 Secarna
11.15.1 Secarna Company Information
11.15.2 Secarna Oligonucleotide Therapy-based Drug Product Offered
11.15.3 Secarna Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2021-2026)
11.15.4 Secarna Main Business Overview
11.15.5 Secarna Latest Developments
11.16 MiNA Therapeutics
11.16.1 MiNA Therapeutics Company Information
11.16.2 MiNA Therapeutics Oligonucleotide Therapy-based Drug Product Offered
11.16.3 MiNA Therapeutics Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2021-2026)
11.16.4 MiNA Therapeutics Main Business Overview
11.16.5 MiNA Therapeutics Latest Developments
11.17 Sylentis
11.17.1 Sylentis Company Information
11.17.2 Sylentis Oligonucleotide Therapy-based Drug Product Offered
11.17.3 Sylentis Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2021-2026)
11.17.4 Sylentis Main Business Overview
11.17.5 Sylentis Latest Developments
11.18 Arrowhead
11.18.1 Arrowhead Company Information
11.18.2 Arrowhead Oligonucleotide Therapy-based Drug Product Offered
11.18.3 Arrowhead Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2021-2026)
11.18.4 Arrowhead Main Business Overview
11.18.5 Arrowhead Latest Developments
11.19 Silence Therapeutics
11.19.1 Silence Therapeutics Company Information
11.19.2 Silence Therapeutics Oligonucleotide Therapy-based Drug Product Offered
11.19.3 Silence Therapeutics Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2021-2026)
11.19.4 Silence Therapeutics Main Business Overview
11.19.5 Silence Therapeutics Latest Developments
11.20 Dicerna
11.20.1 Dicerna Company Information
11.20.2 Dicerna Oligonucleotide Therapy-based Drug Product Offered
11.20.3 Dicerna Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2021-2026)
11.20.4 Dicerna Main Business Overview
11.20.5 Dicerna Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Oligonucleotide Therapy-based Drug Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Oligonucleotide Therapy-based Drug Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Antisense Oligonucleotides (ASO)
Table 4. Major Players of siRNA
Table 5. Major Players of mRNA
Table 6. Oligonucleotide Therapy-based Drug Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 7. Global Oligonucleotide Therapy-based Drug Market Size by Type (2021-2026) & ($ millions)
Table 8. Global Oligonucleotide Therapy-based Drug Market Size Market Share by Type (2021-2026)
Table 9. Oligonucleotide Therapy-based Drug Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 10. Global Oligonucleotide Therapy-based Drug Market Size by Application (2021-2026) & ($ millions)
Table 11. Global Oligonucleotide Therapy-based Drug Market Size Market Share by Application (2021-2026)
Table 12. Global Oligonucleotide Therapy-based Drug Revenue by Player (2021-2026) & ($ millions)
Table 13. Global Oligonucleotide Therapy-based Drug Revenue Market Share by Player (2021-2026)
Table 14. Oligonucleotide Therapy-based Drug Key Players Head office and Products Offered
Table 15. Oligonucleotide Therapy-based Drug Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 16. New Products and Potential Entrants
Table 17. Mergers & Acquisitions, Expansion
Table 18. Global Oligonucleotide Therapy-based Drug Market Size by Region (2021-2026) & ($ millions)
Table 19. Global Oligonucleotide Therapy-based Drug Market Size Market Share by Region (2021-2026)
Table 20. Global Oligonucleotide Therapy-based Drug Revenue by Country/Region (2021-2026) & ($ millions)
Table 21. Global Oligonucleotide Therapy-based Drug Revenue Market Share by Country/Region (2021-2026)
Table 22. Americas Oligonucleotide Therapy-based Drug Market Size by Country (2021-2026) & ($ millions)
Table 23. Americas Oligonucleotide Therapy-based Drug Market Size Market Share by Country (2021-2026)
Table 24. Americas Oligonucleotide Therapy-based Drug Market Size by Type (2021-2026) & ($ millions)
Table 25. Americas Oligonucleotide Therapy-based Drug Market Size Market Share by Type (2021-2026)
Table 26. Americas Oligonucleotide Therapy-based Drug Market Size by Application (2021-2026) & ($ millions)
Table 27. Americas Oligonucleotide Therapy-based Drug Market Size Market Share by Application (2021-2026)
Table 28. APAC Oligonucleotide Therapy-based Drug Market Size by Region (2021-2026) & ($ millions)
Table 29. APAC Oligonucleotide Therapy-based Drug Market Size Market Share by Region (2021-2026)
Table 30. APAC Oligonucleotide Therapy-based Drug Market Size by Type (2021-2026) & ($ millions)
Table 31. APAC Oligonucleotide Therapy-based Drug Market Size by Application (2021-2026) & ($ millions)
Table 32. Europe Oligonucleotide Therapy-based Drug Market Size by Country (2021-2026) & ($ millions)
Table 33. Europe Oligonucleotide Therapy-based Drug Market Size Market Share by Country (2021-2026)
Table 34. Europe Oligonucleotide Therapy-based Drug Market Size by Type (2021-2026) & ($ millions)
Table 35. Europe Oligonucleotide Therapy-based Drug Market Size by Application (2021-2026) & ($ millions)
Table 36. Middle East & Africa Oligonucleotide Therapy-based Drug Market Size by Region (2021-2026) & ($ millions)
Table 37. Middle East & Africa Oligonucleotide Therapy-based Drug Market Size by Type (2021-2026) & ($ millions)
Table 38. Middle East & Africa Oligonucleotide Therapy-based Drug Market Size by Application (2021-2026) & ($ millions)
Table 39. Key Market Drivers & Growth Opportunities of Oligonucleotide Therapy-based Drug
Table 40. Key Market Challenges & Risks of Oligonucleotide Therapy-based Drug
Table 41. Key Industry Trends of Oligonucleotide Therapy-based Drug
Table 42. Global Oligonucleotide Therapy-based Drug Market Size Forecast by Region (2027-2032) & ($ millions)
Table 43. Global Oligonucleotide Therapy-based Drug Market Size Market Share Forecast by Region (2027-2032)
Table 44. Global Oligonucleotide Therapy-based Drug Market Size Forecast by Type (2027-2032) & ($ millions)
Table 45. Global Oligonucleotide Therapy-based Drug Market Size Forecast by Application (2027-2032) & ($ millions)
Table 46. Sarepta Therapeutics Details, Company Type, Oligonucleotide Therapy-based Drug Area Served and Its Competitors
Table 47. Sarepta Therapeutics Oligonucleotide Therapy-based Drug Product Offered
Table 48. Sarepta Therapeutics Oligonucleotide Therapy-based Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 49. Sarepta Therapeutics Main Business
Table 50. Sarepta Therapeutics Latest Developments
Table 51. Ionis Pharmaceuticals Details, Company Type, Oligonucleotide Therapy-based Drug Area Served and Its Competitors
Table 52. Ionis Pharmaceuticals Oligonucleotide Therapy-based Drug Product Offered
Table 53. Ionis Pharmaceuticals Oligonucleotide Therapy-based Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 54. Ionis Pharmaceuticals Main Business
Table 55. Ionis Pharmaceuticals Latest Developments
Table 56. Alnylam Details, Company Type, Oligonucleotide Therapy-based Drug Area Served and Its Competitors
Table 57. Alnylam Oligonucleotide Therapy-based Drug Product Offered
Table 58. Alnylam Oligonucleotide Therapy-based Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 59. Alnylam Main Business
Table 60. Alnylam Latest Developments
Table 61. Biogen Details, Company Type, Oligonucleotide Therapy-based Drug Area Served and Its Competitors
Table 62. Biogen Oligonucleotide Therapy-based Drug Product Offered
Table 63. Biogen Oligonucleotide Therapy-based Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 64. Biogen Main Business
Table 65. Biogen Latest Developments
Table 66. Nippon Shinyaku Details, Company Type, Oligonucleotide Therapy-based Drug Area Served and Its Competitors
Table 67. Nippon Shinyaku Oligonucleotide Therapy-based Drug Product Offered
Table 68. Nippon Shinyaku Oligonucleotide Therapy-based Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 69. Nippon Shinyaku Main Business
Table 70. Nippon Shinyaku Latest Developments
Table 71. Sobi Details, Company Type, Oligonucleotide Therapy-based Drug Area Served and Its Competitors
Table 72. Sobi Oligonucleotide Therapy-based Drug Product Offered
Table 73. Sobi Oligonucleotide Therapy-based Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 74. Sobi Main Business
Table 75. Sobi Latest Developments
Table 76. Novartis Details, Company Type, Oligonucleotide Therapy-based Drug Area Served and Its Competitors
Table 77. Novartis Oligonucleotide Therapy-based Drug Product Offered
Table 78. Novartis Oligonucleotide Therapy-based Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 79. Novartis Main Business
Table 80. Novartis Latest Developments
Table 81. BioNTech Details, Company Type, Oligonucleotide Therapy-based Drug Area Served and Its Competitors
Table 82. BioNTech Oligonucleotide Therapy-based Drug Product Offered
Table 83. BioNTech Oligonucleotide Therapy-based Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 84. BioNTech Main Business
Table 85. BioNTech Latest Developments
Table 86. Pfizer Details, Company Type, Oligonucleotide Therapy-based Drug Area Served and Its Competitors
Table 87. Pfizer Oligonucleotide Therapy-based Drug Product Offered
Table 88. Pfizer Oligonucleotide Therapy-based Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 89. Pfizer Main Business
Table 90. Pfizer Latest Developments
Table 91. Moderna Therapeutics Details, Company Type, Oligonucleotide Therapy-based Drug Area Served and Its Competitors
Table 92. Moderna Therapeutics Oligonucleotide Therapy-based Drug Product Offered
Table 93. Moderna Therapeutics Oligonucleotide Therapy-based Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 94. Moderna Therapeutics Main Business
Table 95. Moderna Therapeutics Latest Developments
Table 96. Jazz Pharmaceuticals Details, Company Type, Oligonucleotide Therapy-based Drug Area Served and Its Competitors
Table 97. Jazz Pharmaceuticals Oligonucleotide Therapy-based Drug Product Offered
Table 98. Jazz Pharmaceuticals Oligonucleotide Therapy-based Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 99. Jazz Pharmaceuticals Main Business
Table 100. Jazz Pharmaceuticals Latest Developments
Table 101. CureVac Details, Company Type, Oligonucleotide Therapy-based Drug Area Served and Its Competitors
Table 102. CureVac Oligonucleotide Therapy-based Drug Product Offered
Table 103. CureVac Oligonucleotide Therapy-based Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 104. CureVac Main Business
Table 105. CureVac Latest Developments
Table 106. Regulus Therapeutics Details, Company Type, Oligonucleotide Therapy-based Drug Area Served and Its Competitors
Table 107. Regulus Therapeutics Oligonucleotide Therapy-based Drug Product Offered
Table 108. Regulus Therapeutics Oligonucleotide Therapy-based Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 109. Regulus Therapeutics Main Business
Table 110. Regulus Therapeutics Latest Developments
Table 111. ProQR Details, Company Type, Oligonucleotide Therapy-based Drug Area Served and Its Competitors
Table 112. ProQR Oligonucleotide Therapy-based Drug Product Offered
Table 113. ProQR Oligonucleotide Therapy-based Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 114. ProQR Main Business
Table 115. ProQR Latest Developments
Table 116. Secarna Details, Company Type, Oligonucleotide Therapy-based Drug Area Served and Its Competitors
Table 117. Secarna Oligonucleotide Therapy-based Drug Product Offered
Table 118. Secarna Oligonucleotide Therapy-based Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 119. Secarna Main Business
Table 120. Secarna Latest Developments
Table 121. MiNA Therapeutics Details, Company Type, Oligonucleotide Therapy-based Drug Area Served and Its Competitors
Table 122. MiNA Therapeutics Oligonucleotide Therapy-based Drug Product Offered
Table 123. MiNA Therapeutics Oligonucleotide Therapy-based Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 124. MiNA Therapeutics Main Business
Table 125. MiNA Therapeutics Latest Developments
Table 126. Sylentis Details, Company Type, Oligonucleotide Therapy-based Drug Area Served and Its Competitors
Table 127. Sylentis Oligonucleotide Therapy-based Drug Product Offered
Table 128. Sylentis Oligonucleotide Therapy-based Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 129. Sylentis Main Business
Table 130. Sylentis Latest Developments
Table 131. Arrowhead Details, Company Type, Oligonucleotide Therapy-based Drug Area Served and Its Competitors
Table 132. Arrowhead Oligonucleotide Therapy-based Drug Product Offered
Table 133. Arrowhead Oligonucleotide Therapy-based Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 134. Arrowhead Main Business
Table 135. Arrowhead Latest Developments
Table 136. Silence Therapeutics Details, Company Type, Oligonucleotide Therapy-based Drug Area Served and Its Competitors
Table 137. Silence Therapeutics Oligonucleotide Therapy-based Drug Product Offered
Table 138. Silence Therapeutics Oligonucleotide Therapy-based Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 139. Silence Therapeutics Main Business
Table 140. Silence Therapeutics Latest Developments
Table 141. Dicerna Details, Company Type, Oligonucleotide Therapy-based Drug Area Served and Its Competitors
Table 142. Dicerna Oligonucleotide Therapy-based Drug Product Offered
Table 143. Dicerna Oligonucleotide Therapy-based Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 144. Dicerna Main Business
Table 145. Dicerna Latest Developments
Table 1. Oligonucleotide Therapy-based Drug Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Oligonucleotide Therapy-based Drug Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Antisense Oligonucleotides (ASO)
Table 4. Major Players of siRNA
Table 5. Major Players of mRNA
Table 6. Oligonucleotide Therapy-based Drug Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 7. Global Oligonucleotide Therapy-based Drug Market Size by Type (2021-2026) & ($ millions)
Table 8. Global Oligonucleotide Therapy-based Drug Market Size Market Share by Type (2021-2026)
Table 9. Oligonucleotide Therapy-based Drug Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 10. Global Oligonucleotide Therapy-based Drug Market Size by Application (2021-2026) & ($ millions)
Table 11. Global Oligonucleotide Therapy-based Drug Market Size Market Share by Application (2021-2026)
Table 12. Global Oligonucleotide Therapy-based Drug Revenue by Player (2021-2026) & ($ millions)
Table 13. Global Oligonucleotide Therapy-based Drug Revenue Market Share by Player (2021-2026)
Table 14. Oligonucleotide Therapy-based Drug Key Players Head office and Products Offered
Table 15. Oligonucleotide Therapy-based Drug Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 16. New Products and Potential Entrants
Table 17. Mergers & Acquisitions, Expansion
Table 18. Global Oligonucleotide Therapy-based Drug Market Size by Region (2021-2026) & ($ millions)
Table 19. Global Oligonucleotide Therapy-based Drug Market Size Market Share by Region (2021-2026)
Table 20. Global Oligonucleotide Therapy-based Drug Revenue by Country/Region (2021-2026) & ($ millions)
Table 21. Global Oligonucleotide Therapy-based Drug Revenue Market Share by Country/Region (2021-2026)
Table 22. Americas Oligonucleotide Therapy-based Drug Market Size by Country (2021-2026) & ($ millions)
Table 23. Americas Oligonucleotide Therapy-based Drug Market Size Market Share by Country (2021-2026)
Table 24. Americas Oligonucleotide Therapy-based Drug Market Size by Type (2021-2026) & ($ millions)
Table 25. Americas Oligonucleotide Therapy-based Drug Market Size Market Share by Type (2021-2026)
Table 26. Americas Oligonucleotide Therapy-based Drug Market Size by Application (2021-2026) & ($ millions)
Table 27. Americas Oligonucleotide Therapy-based Drug Market Size Market Share by Application (2021-2026)
Table 28. APAC Oligonucleotide Therapy-based Drug Market Size by Region (2021-2026) & ($ millions)
Table 29. APAC Oligonucleotide Therapy-based Drug Market Size Market Share by Region (2021-2026)
Table 30. APAC Oligonucleotide Therapy-based Drug Market Size by Type (2021-2026) & ($ millions)
Table 31. APAC Oligonucleotide Therapy-based Drug Market Size by Application (2021-2026) & ($ millions)
Table 32. Europe Oligonucleotide Therapy-based Drug Market Size by Country (2021-2026) & ($ millions)
Table 33. Europe Oligonucleotide Therapy-based Drug Market Size Market Share by Country (2021-2026)
Table 34. Europe Oligonucleotide Therapy-based Drug Market Size by Type (2021-2026) & ($ millions)
Table 35. Europe Oligonucleotide Therapy-based Drug Market Size by Application (2021-2026) & ($ millions)
Table 36. Middle East & Africa Oligonucleotide Therapy-based Drug Market Size by Region (2021-2026) & ($ millions)
Table 37. Middle East & Africa Oligonucleotide Therapy-based Drug Market Size by Type (2021-2026) & ($ millions)
Table 38. Middle East & Africa Oligonucleotide Therapy-based Drug Market Size by Application (2021-2026) & ($ millions)
Table 39. Key Market Drivers & Growth Opportunities of Oligonucleotide Therapy-based Drug
Table 40. Key Market Challenges & Risks of Oligonucleotide Therapy-based Drug
Table 41. Key Industry Trends of Oligonucleotide Therapy-based Drug
Table 42. Global Oligonucleotide Therapy-based Drug Market Size Forecast by Region (2027-2032) & ($ millions)
Table 43. Global Oligonucleotide Therapy-based Drug Market Size Market Share Forecast by Region (2027-2032)
Table 44. Global Oligonucleotide Therapy-based Drug Market Size Forecast by Type (2027-2032) & ($ millions)
Table 45. Global Oligonucleotide Therapy-based Drug Market Size Forecast by Application (2027-2032) & ($ millions)
Table 46. Sarepta Therapeutics Details, Company Type, Oligonucleotide Therapy-based Drug Area Served and Its Competitors
Table 47. Sarepta Therapeutics Oligonucleotide Therapy-based Drug Product Offered
Table 48. Sarepta Therapeutics Oligonucleotide Therapy-based Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 49. Sarepta Therapeutics Main Business
Table 50. Sarepta Therapeutics Latest Developments
Table 51. Ionis Pharmaceuticals Details, Company Type, Oligonucleotide Therapy-based Drug Area Served and Its Competitors
Table 52. Ionis Pharmaceuticals Oligonucleotide Therapy-based Drug Product Offered
Table 53. Ionis Pharmaceuticals Oligonucleotide Therapy-based Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 54. Ionis Pharmaceuticals Main Business
Table 55. Ionis Pharmaceuticals Latest Developments
Table 56. Alnylam Details, Company Type, Oligonucleotide Therapy-based Drug Area Served and Its Competitors
Table 57. Alnylam Oligonucleotide Therapy-based Drug Product Offered
Table 58. Alnylam Oligonucleotide Therapy-based Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 59. Alnylam Main Business
Table 60. Alnylam Latest Developments
Table 61. Biogen Details, Company Type, Oligonucleotide Therapy-based Drug Area Served and Its Competitors
Table 62. Biogen Oligonucleotide Therapy-based Drug Product Offered
Table 63. Biogen Oligonucleotide Therapy-based Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 64. Biogen Main Business
Table 65. Biogen Latest Developments
Table 66. Nippon Shinyaku Details, Company Type, Oligonucleotide Therapy-based Drug Area Served and Its Competitors
Table 67. Nippon Shinyaku Oligonucleotide Therapy-based Drug Product Offered
Table 68. Nippon Shinyaku Oligonucleotide Therapy-based Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 69. Nippon Shinyaku Main Business
Table 70. Nippon Shinyaku Latest Developments
Table 71. Sobi Details, Company Type, Oligonucleotide Therapy-based Drug Area Served and Its Competitors
Table 72. Sobi Oligonucleotide Therapy-based Drug Product Offered
Table 73. Sobi Oligonucleotide Therapy-based Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 74. Sobi Main Business
Table 75. Sobi Latest Developments
Table 76. Novartis Details, Company Type, Oligonucleotide Therapy-based Drug Area Served and Its Competitors
Table 77. Novartis Oligonucleotide Therapy-based Drug Product Offered
Table 78. Novartis Oligonucleotide Therapy-based Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 79. Novartis Main Business
Table 80. Novartis Latest Developments
Table 81. BioNTech Details, Company Type, Oligonucleotide Therapy-based Drug Area Served and Its Competitors
Table 82. BioNTech Oligonucleotide Therapy-based Drug Product Offered
Table 83. BioNTech Oligonucleotide Therapy-based Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 84. BioNTech Main Business
Table 85. BioNTech Latest Developments
Table 86. Pfizer Details, Company Type, Oligonucleotide Therapy-based Drug Area Served and Its Competitors
Table 87. Pfizer Oligonucleotide Therapy-based Drug Product Offered
Table 88. Pfizer Oligonucleotide Therapy-based Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 89. Pfizer Main Business
Table 90. Pfizer Latest Developments
Table 91. Moderna Therapeutics Details, Company Type, Oligonucleotide Therapy-based Drug Area Served and Its Competitors
Table 92. Moderna Therapeutics Oligonucleotide Therapy-based Drug Product Offered
Table 93. Moderna Therapeutics Oligonucleotide Therapy-based Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 94. Moderna Therapeutics Main Business
Table 95. Moderna Therapeutics Latest Developments
Table 96. Jazz Pharmaceuticals Details, Company Type, Oligonucleotide Therapy-based Drug Area Served and Its Competitors
Table 97. Jazz Pharmaceuticals Oligonucleotide Therapy-based Drug Product Offered
Table 98. Jazz Pharmaceuticals Oligonucleotide Therapy-based Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 99. Jazz Pharmaceuticals Main Business
Table 100. Jazz Pharmaceuticals Latest Developments
Table 101. CureVac Details, Company Type, Oligonucleotide Therapy-based Drug Area Served and Its Competitors
Table 102. CureVac Oligonucleotide Therapy-based Drug Product Offered
Table 103. CureVac Oligonucleotide Therapy-based Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 104. CureVac Main Business
Table 105. CureVac Latest Developments
Table 106. Regulus Therapeutics Details, Company Type, Oligonucleotide Therapy-based Drug Area Served and Its Competitors
Table 107. Regulus Therapeutics Oligonucleotide Therapy-based Drug Product Offered
Table 108. Regulus Therapeutics Oligonucleotide Therapy-based Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 109. Regulus Therapeutics Main Business
Table 110. Regulus Therapeutics Latest Developments
Table 111. ProQR Details, Company Type, Oligonucleotide Therapy-based Drug Area Served and Its Competitors
Table 112. ProQR Oligonucleotide Therapy-based Drug Product Offered
Table 113. ProQR Oligonucleotide Therapy-based Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 114. ProQR Main Business
Table 115. ProQR Latest Developments
Table 116. Secarna Details, Company Type, Oligonucleotide Therapy-based Drug Area Served and Its Competitors
Table 117. Secarna Oligonucleotide Therapy-based Drug Product Offered
Table 118. Secarna Oligonucleotide Therapy-based Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 119. Secarna Main Business
Table 120. Secarna Latest Developments
Table 121. MiNA Therapeutics Details, Company Type, Oligonucleotide Therapy-based Drug Area Served and Its Competitors
Table 122. MiNA Therapeutics Oligonucleotide Therapy-based Drug Product Offered
Table 123. MiNA Therapeutics Oligonucleotide Therapy-based Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 124. MiNA Therapeutics Main Business
Table 125. MiNA Therapeutics Latest Developments
Table 126. Sylentis Details, Company Type, Oligonucleotide Therapy-based Drug Area Served and Its Competitors
Table 127. Sylentis Oligonucleotide Therapy-based Drug Product Offered
Table 128. Sylentis Oligonucleotide Therapy-based Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 129. Sylentis Main Business
Table 130. Sylentis Latest Developments
Table 131. Arrowhead Details, Company Type, Oligonucleotide Therapy-based Drug Area Served and Its Competitors
Table 132. Arrowhead Oligonucleotide Therapy-based Drug Product Offered
Table 133. Arrowhead Oligonucleotide Therapy-based Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 134. Arrowhead Main Business
Table 135. Arrowhead Latest Developments
Table 136. Silence Therapeutics Details, Company Type, Oligonucleotide Therapy-based Drug Area Served and Its Competitors
Table 137. Silence Therapeutics Oligonucleotide Therapy-based Drug Product Offered
Table 138. Silence Therapeutics Oligonucleotide Therapy-based Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 139. Silence Therapeutics Main Business
Table 140. Silence Therapeutics Latest Developments
Table 141. Dicerna Details, Company Type, Oligonucleotide Therapy-based Drug Area Served and Its Competitors
Table 142. Dicerna Oligonucleotide Therapy-based Drug Product Offered
Table 143. Dicerna Oligonucleotide Therapy-based Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 144. Dicerna Main Business
Table 145. Dicerna Latest Developments
LIST OF FIGURES
Figure 1. Oligonucleotide Therapy-based Drug Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Oligonucleotide Therapy-based Drug Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Oligonucleotide Therapy-based Drug Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Oligonucleotide Therapy-based Drug Sales Market Share by Country/Region (2025)
Figure 8. Oligonucleotide Therapy-based Drug Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Oligonucleotide Therapy-based Drug Market Size Market Share by Type in 2025
Figure 10. Oligonucleotide Therapy-based Drug in Neuromuscular Diseases
Figure 11. Global Oligonucleotide Therapy-based Drug Market: Neuromuscular Diseases (2021-2026) & ($ millions)
Figure 12. Oligonucleotide Therapy-based Drug in hATTR
Figure 13. Global Oligonucleotide Therapy-based Drug Market: hATTR (2021-2026) & ($ millions)
Figure 14. Oligonucleotide Therapy-based Drug in COVID-19
Figure 15. Global Oligonucleotide Therapy-based Drug Market: COVID-19 (2021-2026) & ($ millions)
Figure 16. Oligonucleotide Therapy-based Drug in Other
Figure 17. Global Oligonucleotide Therapy-based Drug Market: Other (2021-2026) & ($ millions)
Figure 18. Global Oligonucleotide Therapy-based Drug Market Size Market Share by Application in 2025
Figure 19. Global Oligonucleotide Therapy-based Drug Revenue Market Share by Player in 2025
Figure 20. Global Oligonucleotide Therapy-based Drug Market Size Market Share by Region (2021-2026)
Figure 21. Americas Oligonucleotide Therapy-based Drug Market Size 2021-2026 ($ millions)
Figure 22. APAC Oligonucleotide Therapy-based Drug Market Size 2021-2026 ($ millions)
Figure 23. Europe Oligonucleotide Therapy-based Drug Market Size 2021-2026 ($ millions)
Figure 24. Middle East & Africa Oligonucleotide Therapy-based Drug Market Size 2021-2026 ($ millions)
Figure 25. Americas Oligonucleotide Therapy-based Drug Value Market Share by Country in 2025
Figure 26. United States Oligonucleotide Therapy-based Drug Market Size Growth 2021-2026 ($ millions)
Figure 27. Canada Oligonucleotide Therapy-based Drug Market Size Growth 2021-2026 ($ millions)
Figure 28. Mexico Oligonucleotide Therapy-based Drug Market Size Growth 2021-2026 ($ millions)
Figure 29. Brazil Oligonucleotide Therapy-based Drug Market Size Growth 2021-2026 ($ millions)
Figure 30. APAC Oligonucleotide Therapy-based Drug Market Size Market Share by Region in 2025
Figure 31. APAC Oligonucleotide Therapy-based Drug Market Size Market Share by Type (2021-2026)
Figure 32. APAC Oligonucleotide Therapy-based Drug Market Size Market Share by Application (2021-2026)
Figure 33. China Oligonucleotide Therapy-based Drug Market Size Growth 2021-2026 ($ millions)
Figure 34. Japan Oligonucleotide Therapy-based Drug Market Size Growth 2021-2026 ($ millions)
Figure 35. South Korea Oligonucleotide Therapy-based Drug Market Size Growth 2021-2026 ($ millions)
Figure 36. Southeast Asia Oligonucleotide Therapy-based Drug Market Size Growth 2021-2026 ($ millions)
Figure 37. India Oligonucleotide Therapy-based Drug Market Size Growth 2021-2026 ($ millions)
Figure 38. Australia Oligonucleotide Therapy-based Drug Market Size Growth 2021-2026 ($ millions)
Figure 39. Europe Oligonucleotide Therapy-based Drug Market Size Market Share by Country in 2025
Figure 40. Europe Oligonucleotide Therapy-based Drug Market Size Market Share by Type (2021-2026)
Figure 41. Europe Oligonucleotide Therapy-based Drug Market Size Market Share by Application (2021-2026)
Figure 42. Germany Oligonucleotide Therapy-based Drug Market Size Growth 2021-2026 ($ millions)
Figure 43. France Oligonucleotide Therapy-based Drug Market Size Growth 2021-2026 ($ millions)
Figure 44. UK Oligonucleotide Therapy-based Drug Market Size Growth 2021-2026 ($ millions)
Figure 45. Italy Oligonucleotide Therapy-based Drug Market Size Growth 2021-2026 ($ millions)
Figure 46. Russia Oligonucleotide Therapy-based Drug Market Size Growth 2021-2026 ($ millions)
Figure 47. Middle East & Africa Oligonucleotide Therapy-based Drug Market Size Market Share by Region (2021-2026)
Figure 48. Middle East & Africa Oligonucleotide Therapy-based Drug Market Size Market Share by Type (2021-2026)
Figure 49. Middle East & Africa Oligonucleotide Therapy-based Drug Market Size Market Share by Application (2021-2026)
Figure 50. Egypt Oligonucleotide Therapy-based Drug Market Size Growth 2021-2026 ($ millions)
Figure 51. South Africa Oligonucleotide Therapy-based Drug Market Size Growth 2021-2026 ($ millions)
Figure 52. Israel Oligonucleotide Therapy-based Drug Market Size Growth 2021-2026 ($ millions)
Figure 53. Turkey Oligonucleotide Therapy-based Drug Market Size Growth 2021-2026 ($ millions)
Figure 54. GCC Countries Oligonucleotide Therapy-based Drug Market Size Growth 2021-2026 ($ millions)
Figure 55. Americas Oligonucleotide Therapy-based Drug Market Size 2027-2032 ($ millions)
Figure 56. APAC Oligonucleotide Therapy-based Drug Market Size 2027-2032 ($ millions)
Figure 57. Europe Oligonucleotide Therapy-based Drug Market Size 2027-2032 ($ millions)
Figure 58. Middle East & Africa Oligonucleotide Therapy-based Drug Market Size 2027-2032 ($ millions)
Figure 59. United States Oligonucleotide Therapy-based Drug Market Size 2027-2032 ($ millions)
Figure 60. Canada Oligonucleotide Therapy-based Drug Market Size 2027-2032 ($ millions)
Figure 61. Mexico Oligonucleotide Therapy-based Drug Market Size 2027-2032 ($ millions)
Figure 62. Brazil Oligonucleotide Therapy-based Drug Market Size 2027-2032 ($ millions)
Figure 63. China Oligonucleotide Therapy-based Drug Market Size 2027-2032 ($ millions)
Figure 64. Japan Oligonucleotide Therapy-based Drug Market Size 2027-2032 ($ millions)
Figure 65. Korea Oligonucleotide Therapy-based Drug Market Size 2027-2032 ($ millions)
Figure 66. Southeast Asia Oligonucleotide Therapy-based Drug Market Size 2027-2032 ($ millions)
Figure 67. India Oligonucleotide Therapy-based Drug Market Size 2027-2032 ($ millions)
Figure 68. Australia Oligonucleotide Therapy-based Drug Market Size 2027-2032 ($ millions)
Figure 69. Germany Oligonucleotide Therapy-based Drug Market Size 2027-2032 ($ millions)
Figure 70. France Oligonucleotide Therapy-based Drug Market Size 2027-2032 ($ millions)
Figure 71. UK Oligonucleotide Therapy-based Drug Market Size 2027-2032 ($ millions)
Figure 72. Italy Oligonucleotide Therapy-based Drug Market Size 2027-2032 ($ millions)
Figure 73. Russia Oligonucleotide Therapy-based Drug Market Size 2027-2032 ($ millions)
Figure 74. Egypt Oligonucleotide Therapy-based Drug Market Size 2027-2032 ($ millions)
Figure 75. South Africa Oligonucleotide Therapy-based Drug Market Size 2027-2032 ($ millions)
Figure 76. Israel Oligonucleotide Therapy-based Drug Market Size 2027-2032 ($ millions)
Figure 77. Turkey Oligonucleotide Therapy-based Drug Market Size 2027-2032 ($ millions)
Figure 78. Global Oligonucleotide Therapy-based Drug Market Size Market Share Forecast by Type (2027-2032)
Figure 79. Global Oligonucleotide Therapy-based Drug Market Size Market Share Forecast by Application (2027-2032)
Figure 80. GCC Countries Oligonucleotide Therapy-based Drug Market Size 2027-2032 ($ millions)
Figure 1. Oligonucleotide Therapy-based Drug Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Oligonucleotide Therapy-based Drug Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Oligonucleotide Therapy-based Drug Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Oligonucleotide Therapy-based Drug Sales Market Share by Country/Region (2025)
Figure 8. Oligonucleotide Therapy-based Drug Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Oligonucleotide Therapy-based Drug Market Size Market Share by Type in 2025
Figure 10. Oligonucleotide Therapy-based Drug in Neuromuscular Diseases
Figure 11. Global Oligonucleotide Therapy-based Drug Market: Neuromuscular Diseases (2021-2026) & ($ millions)
Figure 12. Oligonucleotide Therapy-based Drug in hATTR
Figure 13. Global Oligonucleotide Therapy-based Drug Market: hATTR (2021-2026) & ($ millions)
Figure 14. Oligonucleotide Therapy-based Drug in COVID-19
Figure 15. Global Oligonucleotide Therapy-based Drug Market: COVID-19 (2021-2026) & ($ millions)
Figure 16. Oligonucleotide Therapy-based Drug in Other
Figure 17. Global Oligonucleotide Therapy-based Drug Market: Other (2021-2026) & ($ millions)
Figure 18. Global Oligonucleotide Therapy-based Drug Market Size Market Share by Application in 2025
Figure 19. Global Oligonucleotide Therapy-based Drug Revenue Market Share by Player in 2025
Figure 20. Global Oligonucleotide Therapy-based Drug Market Size Market Share by Region (2021-2026)
Figure 21. Americas Oligonucleotide Therapy-based Drug Market Size 2021-2026 ($ millions)
Figure 22. APAC Oligonucleotide Therapy-based Drug Market Size 2021-2026 ($ millions)
Figure 23. Europe Oligonucleotide Therapy-based Drug Market Size 2021-2026 ($ millions)
Figure 24. Middle East & Africa Oligonucleotide Therapy-based Drug Market Size 2021-2026 ($ millions)
Figure 25. Americas Oligonucleotide Therapy-based Drug Value Market Share by Country in 2025
Figure 26. United States Oligonucleotide Therapy-based Drug Market Size Growth 2021-2026 ($ millions)
Figure 27. Canada Oligonucleotide Therapy-based Drug Market Size Growth 2021-2026 ($ millions)
Figure 28. Mexico Oligonucleotide Therapy-based Drug Market Size Growth 2021-2026 ($ millions)
Figure 29. Brazil Oligonucleotide Therapy-based Drug Market Size Growth 2021-2026 ($ millions)
Figure 30. APAC Oligonucleotide Therapy-based Drug Market Size Market Share by Region in 2025
Figure 31. APAC Oligonucleotide Therapy-based Drug Market Size Market Share by Type (2021-2026)
Figure 32. APAC Oligonucleotide Therapy-based Drug Market Size Market Share by Application (2021-2026)
Figure 33. China Oligonucleotide Therapy-based Drug Market Size Growth 2021-2026 ($ millions)
Figure 34. Japan Oligonucleotide Therapy-based Drug Market Size Growth 2021-2026 ($ millions)
Figure 35. South Korea Oligonucleotide Therapy-based Drug Market Size Growth 2021-2026 ($ millions)
Figure 36. Southeast Asia Oligonucleotide Therapy-based Drug Market Size Growth 2021-2026 ($ millions)
Figure 37. India Oligonucleotide Therapy-based Drug Market Size Growth 2021-2026 ($ millions)
Figure 38. Australia Oligonucleotide Therapy-based Drug Market Size Growth 2021-2026 ($ millions)
Figure 39. Europe Oligonucleotide Therapy-based Drug Market Size Market Share by Country in 2025
Figure 40. Europe Oligonucleotide Therapy-based Drug Market Size Market Share by Type (2021-2026)
Figure 41. Europe Oligonucleotide Therapy-based Drug Market Size Market Share by Application (2021-2026)
Figure 42. Germany Oligonucleotide Therapy-based Drug Market Size Growth 2021-2026 ($ millions)
Figure 43. France Oligonucleotide Therapy-based Drug Market Size Growth 2021-2026 ($ millions)
Figure 44. UK Oligonucleotide Therapy-based Drug Market Size Growth 2021-2026 ($ millions)
Figure 45. Italy Oligonucleotide Therapy-based Drug Market Size Growth 2021-2026 ($ millions)
Figure 46. Russia Oligonucleotide Therapy-based Drug Market Size Growth 2021-2026 ($ millions)
Figure 47. Middle East & Africa Oligonucleotide Therapy-based Drug Market Size Market Share by Region (2021-2026)
Figure 48. Middle East & Africa Oligonucleotide Therapy-based Drug Market Size Market Share by Type (2021-2026)
Figure 49. Middle East & Africa Oligonucleotide Therapy-based Drug Market Size Market Share by Application (2021-2026)
Figure 50. Egypt Oligonucleotide Therapy-based Drug Market Size Growth 2021-2026 ($ millions)
Figure 51. South Africa Oligonucleotide Therapy-based Drug Market Size Growth 2021-2026 ($ millions)
Figure 52. Israel Oligonucleotide Therapy-based Drug Market Size Growth 2021-2026 ($ millions)
Figure 53. Turkey Oligonucleotide Therapy-based Drug Market Size Growth 2021-2026 ($ millions)
Figure 54. GCC Countries Oligonucleotide Therapy-based Drug Market Size Growth 2021-2026 ($ millions)
Figure 55. Americas Oligonucleotide Therapy-based Drug Market Size 2027-2032 ($ millions)
Figure 56. APAC Oligonucleotide Therapy-based Drug Market Size 2027-2032 ($ millions)
Figure 57. Europe Oligonucleotide Therapy-based Drug Market Size 2027-2032 ($ millions)
Figure 58. Middle East & Africa Oligonucleotide Therapy-based Drug Market Size 2027-2032 ($ millions)
Figure 59. United States Oligonucleotide Therapy-based Drug Market Size 2027-2032 ($ millions)
Figure 60. Canada Oligonucleotide Therapy-based Drug Market Size 2027-2032 ($ millions)
Figure 61. Mexico Oligonucleotide Therapy-based Drug Market Size 2027-2032 ($ millions)
Figure 62. Brazil Oligonucleotide Therapy-based Drug Market Size 2027-2032 ($ millions)
Figure 63. China Oligonucleotide Therapy-based Drug Market Size 2027-2032 ($ millions)
Figure 64. Japan Oligonucleotide Therapy-based Drug Market Size 2027-2032 ($ millions)
Figure 65. Korea Oligonucleotide Therapy-based Drug Market Size 2027-2032 ($ millions)
Figure 66. Southeast Asia Oligonucleotide Therapy-based Drug Market Size 2027-2032 ($ millions)
Figure 67. India Oligonucleotide Therapy-based Drug Market Size 2027-2032 ($ millions)
Figure 68. Australia Oligonucleotide Therapy-based Drug Market Size 2027-2032 ($ millions)
Figure 69. Germany Oligonucleotide Therapy-based Drug Market Size 2027-2032 ($ millions)
Figure 70. France Oligonucleotide Therapy-based Drug Market Size 2027-2032 ($ millions)
Figure 71. UK Oligonucleotide Therapy-based Drug Market Size 2027-2032 ($ millions)
Figure 72. Italy Oligonucleotide Therapy-based Drug Market Size 2027-2032 ($ millions)
Figure 73. Russia Oligonucleotide Therapy-based Drug Market Size 2027-2032 ($ millions)
Figure 74. Egypt Oligonucleotide Therapy-based Drug Market Size 2027-2032 ($ millions)
Figure 75. South Africa Oligonucleotide Therapy-based Drug Market Size 2027-2032 ($ millions)
Figure 76. Israel Oligonucleotide Therapy-based Drug Market Size 2027-2032 ($ millions)
Figure 77. Turkey Oligonucleotide Therapy-based Drug Market Size 2027-2032 ($ millions)
Figure 78. Global Oligonucleotide Therapy-based Drug Market Size Market Share Forecast by Type (2027-2032)
Figure 79. Global Oligonucleotide Therapy-based Drug Market Size Market Share Forecast by Application (2027-2032)
Figure 80. GCC Countries Oligonucleotide Therapy-based Drug Market Size 2027-2032 ($ millions)
